We are live on ! Find out more
ACH

ArrowMark Colorado Holdings Portfolio holdings

AUM $3.76B
1-Year Est. Return 21.77%
This Fund
S&P 500
This Quarter Est. Return
+11.41%
1 Year Est. Return
+21.77%
3 Year Est. Return
+58.74%
5 Year Est. Return
+55.15%
10 Year Est. Return
+679.66%
AUM
$3.04B
AUM Growth
+$2.67B
Cap. Flow
+$2.56B
Cap. Flow %
84.22%
Top 10 Hldgs %
15.71%
Holding
325
New
194
Increased
41
Reduced
19
Closed
24

Sector Composition

Rank Sector Weight
1 Industrials 20.7%
2 Consumer Discretionary 17.16%
3 Technology 15.92%
4 Healthcare 10.03%
5 Financials 8.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRK icon
276
Merck
MRK
$318B
$299K 0.01%
6,588
SHPG
277
CALL
DELISTED
Shire pic
SHPG
$288K 0.01%
2,400
-1,400
-37% -$155K
HSP
278
CALL
DELISTED
HOSPIRA INC
HSP
$279K 0.01%
7,100
+200
+3% +$7.97K
BDX icon
279
CALL
Becton Dickinson
BDX
$48.2B
$270K 0.01%
2,768
+308
+13% +$30.1K
PFE icon
280
CALL
Pfizer
PFE
$153B
$264K 0.01%
+9,697
New +$264K
SYK icon
281
CALL
Stryker
SYK
$130B
$257K 0.01%
3,800
BCR
282
CALL
DELISTED
CR Bard Inc.
BCR
$242K 0.01%
+2,100
New +$241K
KO icon
283
Coca-Cola
KO
$375B
$238K 0.01%
6,286
EW icon
284
CALL
Edwards Lifesciences
EW
$51.7B
$237K 0.01%
20,400
FMS icon
285
CALL
Fresenius Medical Care
FMS
$12.9B
$236K 0.01%
+7,300
New +$238K
CAH icon
286
CALL
Cardinal Health
CAH
$55.4B
$235K 0.01%
4,500
COR icon
287
CALL
Cencora
COR
$61.2B
$232K 0.01%
3,800
JAZZ icon
288
CALL
Jazz Pharmaceuticals
JAZZ
$16.7B
$230K 0.01%
2,500
-800
-24% -$64.5K
NBIX icon
289
CALL
Neurocrine Biosciences
NBIX
$16.6B
$222K 0.01%
19,600
+1,700
+9% +$23.4K
UTHR icon
290
CALL
United Therapeutics
UTHR
$23.1B
$205K 0.01%
+2,600
New +$190K
DGX icon
291
CALL
Quest Diagnostics
DGX
$26.3B
$204K 0.01%
+3,300
New +$198K
HALO icon
292
Halozyme
HALO
$12.2B
$185K 0.01%
+16,763
New +$140K
CLDX icon
293
CALL
Celldex Therapeutics
CLDX
$3.28B
$177K 0.01%
333
STI
294
CALL
DELISTED
SunTrust Banks, Inc.
STI
$165K 0.01%
5,100
CHTP
295
CALL
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$141K ﹤0.01%
+47,000
New +$135K
AVNR
296
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$131K ﹤0.01%
+30,983
New +$147K
IDXX icon
297
CALL
Idexx Laboratories
IDXX
$46.2B
$110K ﹤0.01%
+2,200
New +$106K
AVNR
298
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$64K ﹤0.01%
+15,200
New +$72K
VTRS icon
299
PUT
Viatris
VTRS
$18.9B
$38K ﹤0.01%
+1,000
New +$35.2K
VRTX icon
300
CALL
Vertex Pharmaceuticals
VRTX
$126B
$15K ﹤0.01%
200
-3,800
-95% -$302K

Similar funds

ArrowMark Colorado Holdings's Q3 2013 Portfolio in Review

As of Q3 2013, ArrowMark Colorado Holdings held 325 positions worth $3.04B, up 717% from $372M the previous quarter. Its ten largest holdings account for 16% of the portfolio.

ArrowMark Colorado Holdings deployed $2.56B of net new capital in Q3 2013, opening 194 new positions and adding to 41 existing holdings. Its largest new stake was Wolverine World Wide: 1,966,684 shares worth $57.3M.

By sector, the portfolio is most concentrated in Industrials at 21% of assets, up from 1.1% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was MetLife, an estimated $18.5M trimmed.

  • ArrowMark Colorado Holdings's largest Q3 2013 buy was Wolverine World Wide: 1,966,684 shares worth $57.3M.
  • ArrowMark Colorado Holdings added most to DRESSER-RAND GROUP INC in Q3 2013, an estimated $54.1M increase.
  • ArrowMark Colorado Holdings's biggest Q3 2013 reduction was MetLife, cutting an estimated $18.5M.
  • ArrowMark Colorado Holdings fully exited Global Payments in Q3 2013, selling an estimated $3.28M.
  • ArrowMark Colorado Holdings's ten largest holdings make up 16% of its $3.04B portfolio in Q3 2013.
  • ArrowMark Colorado Holdings opened 194 new positions and closed 24 in Q3 2013.
  • ArrowMark Colorado Holdings's portfolio value rose 717% quarter-over-quarter to $3.04B.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2013, filed 14 Nov 2013.